Pathology: breast cancer - adjuvant; es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 1st Line (L1); la/mBC - HER2 positive - 2nd Line (L2); la/mBC - HR-positive - 1st line (L1);
| breast cancer - adjuvant | es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HER2 positive - 2nd Line (L2) | la/mBC - HR-positive - 1st line (L1) | |||||||||||||||||||
| BCIRG-006 (TCH vs AC-T), 2011 | BCIRG-006 (AC-TH vs TCH), 2011 | BCIRG-006 (AC-TH vs AC-T), 2011 | ExteNET, 2016 | APHINITY, 2017 | GeparQuinto, 2012 | PERTAIN, 2018 | CLEOPATRA, 2012 | PUFFIN, 2020 | SYSUCC-002, 2022 | LUX-Breast 1, 2016 | WJOG6110B/ELTOP, 2018 | EGF104900, 2010 | ExteNET, 2016 | NALA, 2020 | NALA (brain metastases), 2020 | HER2CLIMB (patients with brain metastases), 2020 | HER2CLIMB, 2020 | CALGB 40302, 2014 | EGF30008 (HER2-positive), 2009 | EGF30008 (all population), 2009 | SYSUCC-002, 2022 | ||
| trastuzumab plus endocrine therapy | 2 | T1 | T1 | ||||||||||||||||||||
| neratinib plus capecitabine | 2 | T1 | T1 | ||||||||||||||||||||
| tucatinib plus trastuzumab plus capecitabine | 2 | T1 | T1 | ||||||||||||||||||||
| pertuzumab plus trastuzumab | 2 | T1 | T1 | ||||||||||||||||||||
| neratinib | 2 | T1 | T1 | ||||||||||||||||||||
| pertuzumab plus trastuzumab plus docetaxel | 2 | T1 | T1 | ||||||||||||||||||||
| doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab | 2 | T1 | T1 | ||||||||||||||||||||
| lapatinib plus letrozole | 2 | T1 | T1 | ||||||||||||||||||||
| lapatinib plus capecitabine | 1 | T1 | T0 | T0 | |||||||||||||||||||
| afatinib plus vinorelbine | 1 | T1 | |||||||||||||||||||||
| lapatinib plus fulvestrant | 1 | T1 | |||||||||||||||||||||
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 | |||||||||||||||||||||
| docetaxel plus carboplatin with trastuzumab followed by trastuzumab | 1 | T1 | T0 | ||||||||||||||||||||
| lapatinib plus trastuzumab | 1 | T1 | |||||||||||||||||||||
| trastuzumab plus chemotherapy | 0 | T0 | T0 | ||||||||||||||||||||
| trastuzumab plus capecitabine | 0 | T0 | T0 | T0 | |||||||||||||||||||
| trastuzumab | 0 | T0 | T0 | ||||||||||||||||||||
| placebo | 0 | T0 | T0 | ||||||||||||||||||||
| trastuzumab plus docetaxel | 0 | T0 | T0 | ||||||||||||||||||||
| trastuzumab plus vinorelbine | 0 | T0 | |||||||||||||||||||||
| fulvestrant | 0 | T0 | |||||||||||||||||||||
| lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 | |||||||||||||||||||||
| doxorubicin plus cyclophosphamide followed by docetaxel | 0 | T0 | T0 | ||||||||||||||||||||
| lapatinib | 0 | T0 | |||||||||||||||||||||
| letrozole | 0 | T0 | T0 | ||||||||||||||||||||